We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Kyowa

News List

KYOWA, Bora Pharmaceuticals Enter Mfg. Pact contractpharma
August 11, 2021
Upon approval in Japan, Bora will be the commercial manufacturing site for the generic product production.
KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan prnasia
August 05, 2021
KYOWA Pharmaceutical Industry Co. Ltd., a premier Japanese pharmaceutical company, has contracted with Bora Pharmaceutical Laboratories Inc. (Zhunan), a division of Bora Pharmaceuticals for the manufacturing of generic product for filing in Japan.
FDA approves Kyowa Kirin’s Nourianz drug for Parkinson’s disease pharmaceutical-technology
September 03, 2019
The US Food and Drug Administration (FDA) has approved Japanese company Kyowa Kirin’s drug Nourianz (istradefylline) as an add-on to the existing drug levodopa/carbidopa to treat adults...
Kyowa Kirin Announces FDA Acceptance of Istradefylline (KW-6002) New Drug Application Resubmission in the US drugs
April 18, 2019
Kyowa Kirin Announces FDA Acceptance of Istradefylline (KW-6002) New Drug Application Resubmission in the US.
Astellas and Lupin’s subsidiary Kyowa enter into an agreement expressbpd
February 28, 2017
Kyowa to exclusively market Quetiapine Fumarate extended-release tablets in Japan